Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Total Liabilities
Everything the company owes to creditors and other parties.
Upstream Bio, Inc.NASDAQ: UPB
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 33.1% from a year ago
Total liabilities stood at $14.06M at the end of Q1 FY2026, up 33.1% from a year earlier and up 0.4% from the prior quarter. Over 3 fiscal years it compounded at -51.7% a year.
Context
- Total liabilities amounted to 4.4% of total assets at the end of Q1 FY2026, up 2.1 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +33.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 14M USD
- Year-over-year change
- +18.0%
- 3-year CAGR
- -51.7%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14M | +18.0% |
| FY2024 | 2024-12-31 | 11.87M | -95.1% |
| FY2023 | 2023-12-31 | 240.32M | +92.8% |
| FY2022 | 2022-12-31 | 124.63M | — |
Total Liabilities vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +33.1% is the 2nd highest of 10, against a peer median of +1.3%.
- Total liabilities amounts to 4.4% of total assets for UPB, versus a peer median of 12.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.19B USD | -13.2% | -23.3% | 113.9% | |
| Mar 2026 | $431.05M USD | +1.3% | +149.9% | 91.2% | |
| Mar 2026 | $411.85M USD | +732.9% | -19.1% | 55.1% | |
| Mar 2026 | $137.84M USD | -33.2% | -15.7% | 18.2% | |
| Jun 2026 | $77.45M USD | +22.6% | -28.7% | 8.0% | |
| Mar 2026 | $71.81M USD | -38.4% | -16.3% | 12.3% | |
| Sep 2026 | $48.19M USD | -2.6% | +44.2% | 4.4% | |
| Sep 2026 | $33.06M USD | +7.5% | -18.6% | 4.2% | |
| Sep 2026 | €30.09M EUR | +12.9% | +17.8% | 10.2% | |
UPBUpstream Bio, Inc. | Mar 2026 | $14.06M USD | +33.1% | -51.7% | 4.4% |
| Peer median (excluding UPB) | — | +1.3% | -16.3% | 12.3% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.